Literature DB >> 10943860

Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of a cell surface-targeted plasmin inhibitor.

W H van der Laan1, T Pap, H K Ronday, J M Grimbergen, L G Huisman, J M TeKoppele, F C Breedveld, R E Gay, S Gay, T W Huizinga, J H Verheijen, P H Quax.   

Abstract

OBJECTIVE: Joint destruction in rheumatoid arthritis (RA) is a result of degradation and invasion of the articular cartilage by the pannus tissue. The present study was undertaken to examine the role of the plasminogen activation system in cartilage degradation and invasion by synovial fibroblasts and investigate a novel gene therapeutic approach using a cell surface-targeted plasmin inhibitor (ATF.BPTI).
METHODS: Adenoviral vectors were used for gene transfer. The effects of ATF.BPTI gene transfer on RA synovial fibroblast-dependent cartilage degradation were studied in vitro, and cartilage invasion was studied in vivo in the SCID mouse coimplantation model.
RESULTS: The results indicate that cartilage matrix degradation by rheumatoid synovial fibroblasts is plasmin mediated and depends on urokinase-type plasminogen activator for activation. Targeting plasmin inhibition to the cell surface of the fibroblasts by gene transfer of a cell surface-binding plasmin inhibitor resulted in a significant reduction of cartilage matrix degradation in vitro and of cartilage invasion in vivo. Compared with uninfected rheumatoid synovial fibroblasts, the mean +/-SEM cartilage degradation in vitro was reduced to 87.9+/-0.9% after LacZ gene transfer versus a reduction to 24.0+/-1.6% after ATF.BPTI gene transfer (P<0.0001). The mean +/- SEM in vivo cartilage invasion score was 3.1+/-0.4 in the control-transduced fibroblasts and 1.8+/-0.4 in the ATF.BPTI-transduced fibroblasts (P<0.05).
CONCLUSION: These results indicate a role of the plasminogen activation system in synovial fibroblast-dependent cartilage degradation and invasion in RA, and demonstrate an effective way to inhibit this by gene transfer of a cell surface-targeted plasmin inhibitor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10943860     DOI: 10.1002/1529-0131(200008)43:8<1710::AID-ANR6>3.0.CO;2-Y

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  13 in total

1.  Plasminogen activator inhibitor-1 as a link between pathological fibrinolysis and arthritis of Behçet's disease.

Authors:  M Akif Oztürk; Ihsan Ertenli; Sedat Kiraz; Ibrahim C Haznedaroğlu; Ismail Celik; Serafettin Kirazli; Meral Calgüneri
Journal:  Rheumatol Int       Date:  2003-05-15       Impact factor: 2.631

Review 2.  Gene targeting: roadmap to future therapies.

Authors:  Lars C Huber; Thomas Pap; Ulf Müller-Ladner; Renate E Gay; Steffen Gay
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

3.  Comparison of pancreas juice proteins from cancer versus pancreatitis using quantitative proteomic analysis.

Authors:  Ru Chen; Sheng Pan; Kelly Cooke; Kara White Moyes; Mary P Bronner; David R Goodlett; Ruedi Aebersold; Teresa A Brentnall
Journal:  Pancreas       Date:  2007-01       Impact factor: 3.327

4.  Inflammation, immune reactivity, and angiogenesis in a severe combined immunodeficiency model of rheumatoid arthritis.

Authors:  Laurie S Davis; Marian Sackler; Ruth I Brezinschek; Ellis Lightfoot; Jennifer L Bailey; Nancy Oppenheimer-Marks; Peter E Lipsky
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

5.  Plasminogen activation/plasmin in rheumatoid arthritis: matrix degradation and more.

Authors:  Martin O Judex; Barbara M Mueller
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

6.  The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis.

Authors:  Jinan Li; Annelii Ny; Göran Leonardsson; Kutty Selva Nandakumar; Rikard Holmdahl; Tor Ny
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

7.  Synovial fibroblasts spread rheumatoid arthritis to unaffected joints.

Authors:  Stephanie Lefèvre; Anette Knedla; Christoph Tennie; Andreas Kampmann; Christina Wunrau; Robert Dinser; Adelheid Korb; Eva-Maria Schnäker; Ingo H Tarner; Paul D Robbins; Christopher H Evans; Henning Stürz; Jürgen Steinmeyer; Steffen Gay; Jürgen Schölmerich; Thomas Pap; Ulf Müller-Ladner; Elena Neumann
Journal:  Nat Med       Date:  2009-11-08       Impact factor: 53.440

8.  Discrepancy between mRNA and protein expression of tumour suppressor maspin in synovial tissue may contribute to synovial hyperplasia in rheumatoid arthritis.

Authors:  J Schedel; O Distler; M Woenckhaus; R E Gay; B Simmen; B A Michel; U Müller-Ladner; S Gay
Journal:  Ann Rheum Dis       Date:  2004-10       Impact factor: 19.103

9.  Urokinase-type plasminogen activator and arthritis progression: contrasting roles in systemic and monoarticular arthritis models.

Authors:  Christine M De Nardo; Jason C Lenzo; Jarrad Pobjoy; John A Hamilton; Andrew D Cook
Journal:  Arthritis Res Ther       Date:  2010-10-25       Impact factor: 5.156

Review 10.  Proteinases in the joint: clinical relevance of proteinases in joint destruction.

Authors:  Yvonne Rengel; Caroline Ospelt; Steffen Gay
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.